Thrombin activatable fibrinolysis inhibitor (TAFI): A role in pre-eclampsia?

Clinica Chimica Acta

Volumn 378, Issue 1-2, 2007, Pages 1-6

  Dusse, Luci Maria SantAna ^a,b   Cooper, Alan J ^c   Lwaleed, Bashir A ^b,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Pre eclampsia; Pro TAFI; TAFIa

Indexed keywords

PROTEIN C; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

DNA POLYMORPHISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; REVIEW;

CARBOXYPEPTIDASE U; FEMALE; HUMANS; POLYMORPHISM, GENETIC; PRE-ECLAMPSIA; PREGNANCY; PROTEIN C; PROTEIN PRECURSORS; THROMBIN; THROMBOMODULIN;

EID: 33846926328     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.10.014     Document Type: Review

References (82)

1. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 183 (2000) S1-S22
2. National high blood pressure education program working group report on high pressure in pregnancy. Am J Obstet Gynecol 163 (1990) 1691-1712
3. Stirling Y., Woolf L., North W.R., Seghatchian M.J., and Meade T.W. Hemostasis in normal pregnancy. Thromb Haemost 52 (1984) 176-182
4. Holmes V.A., and Wallace J.M. Haemostasis in normal pregnancy: a balancing act?. Biochem Soc Trans 33 2 (2005) 428-432
5. Brenner B. Hemostatic changes in pregnancy. Thromb Res 114 (2004) 408-414
6. Lanir N., Aharon A., and Brenner B. Haemostatic mechanisms in human placenta. Baillieres Best Pract Res Clin Haematol 16 2 (2003) 183-195
7. Arias F., and Mancilla-Jimenez R. Hepatic fibrinogen deposits in pre-eclampsia. Immunofluorescent evidence. N Engl J Med 295 11 (1976) 578-582
8. McKay D.G. Hematologic evidence of disseminated intravascular coagulation in eclampsia. Obstet Gynecol Surv 27 6 (1972) 399-417
9. Brown M.A. The physiology of preeclampsia. Clin Exp Pharmacol Physiol 22 (1995) 781-791
10. Howie P.W., Prentice C.R., and McNicol G.P. Coagulation, fibrinolysis and platelet function in pre-eclampsia, essential hypertension and placental insufficiency. J Obstet Gynaecol Br Commonw 78 11 (1971) 992-1003
11. Redman C.W., Denson K.W., Beilin L.J., Bolton F.G., and Stirrrat G.M. Factor-VIII consumption in pre-eclampsia. Lancet 2 8051 (1977) 1249-1252
12. VanWijk M.J., Boer K., Berckmans R.J., Meijers J.C., van der Post J.A., and Sturk A. Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 88 3 (2002) 415-420
13. Schjetlein R., Abdelnoor M., Haugen G., Husby H., Sandset P.M., and Wisloff F. Hemostatic variables as independent predictors for fetal growth retardation in preclampsia. Acta Obstet Gynecol Scand 78 3 (1999) 191-197
14. Higgins J.R., Walshe J.J., Darling M.R.N., Norris L., and Bonnar J. Hemostasis in the uteroplacental and peripheral circulations in normotensive and pre-eclamptic pregnancies. Am J Obstet Gynecol 179 (1998) 520-526
15. Weiner C.P., and Brandt J. Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia. Lancet 2 8051 (1977) 1249-1252
16. Rakoczi I., Tallian F., Bagdany S., and Gati I. Platelet life-span in normal pregnancy and pre-eclampsia as determined by a non-radioisotope technique. Thromb Res 15 3-4 (1979) 553-556
17. Redman C.W., Bonnar J., and Beilen L. Early platelet consumption in pre-eclampsia. Br Med J 1 6111 (1978) 467-469
18. Estelles A., Gilabert J., Grancha S., et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe pre-eclampsia. Thromb Haemost 79 (1998) 500-508
19. Hendriks D., Scharpe S., van Sande M., and Lommaert M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 27 5 (1989) 277-285
20. Leurs J., and Hendriks D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and possible risk factor for thrombotic disease. Thromb Haemost 94 (2005) 471-487
21. Hendriks D., Wang W., van Sande, and Scharpe S. Human serum carboxypeptidase U: a new kinase?. Agents Actions Suppl 38 Pt 1 (1992) 407-413
22. Redlitz A., Tan A.K., Eaton D.L., and Plow E.F. Plasma carboxypeptidase as regulators of the plasminogen system. J Clin Invest 96 5 (1995) 2104-2105
23. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., and Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 266 32 (1991) 21833-21838
24. Campbell W., and Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 162 (1989) 933-939
25. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270 (1995) 14477-14484
26. Mosnier L.O., Buijtenhuijs P., Marx P.F., et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 101 (2003) 4844-4846
27. Stromqvist M., Schatteman K., Leurs J., Verkerk R., Andersson J.O., and Johansson T. Immmunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 85 (2001) 12-17
28. Guo X., Morioka A., Kaneko Y., Okada N., Obata K., and Nomura T. Arginine carboxypeptidase (CPR) in human plasma determined with sandwich ELISA. Microbiol Immunol 43 (1999) 691-698
29. Mosnier L.O., Meijers J.C.M., and Bouma B.N. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 85 (2001) 5-11
30. Wang W., Nagashima M., Schneider M., et al. Elements of the primary structure of thrombomodulin required for efficient thrombin-activatable fibrinolysis inhibitor activation. J Biol Chem 275 (2000) 22942-22947
31. Leurs J., Nerme V., Sim Y., and Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2 (2004) 416-423
32. Bajzar L., Moser J., and Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271 (1996) 16603-16608
33. Willemse J.L., and Hendriks D.F. Measurements of pro carboxypeptidase U (TAFI) in human plasma: a laboratory challenge. Clin Chem 52 (2006) 30-36
34. Bouma B.N., and Laurent O.M. Thrombin-activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 (2003/2004) 375-381
35. Neiheim M. Thrombin and fibrinolysis. Chest 124 (2003) 33S-39S
36. Wang W., Boffa M.B., Bajzar L., Walker J.B., and Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 273 42 (1998) 27176-27181
37. Boffa M.D., Hamill J.D., Maret D., Brown D., Scott M.L., and Nesheim M.E. Acute phase mediators modulate thrombin-activatable fibrinolysis inhibitor (TAFI) gene expression in Hep G2 cells. J Biol Chem 278 11 (2003) 9250-9257
38. Campbell W.D., Lazoura E., Okada N., and Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 46 (2002) 131-134
39. Campbell W.D., Okada N., and Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 180 (2001) 162-166
40. Myles T., Nishimura T., Yun T.H., et al. Thrombin-activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 278 (2003) 51059-51067
41. Hall S.W., Nagashima M., Zhao, Morser J., and Leune L.L. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 274 36 (1999) 25510-25516
42. Bell R., Stevens W.K., Jia Z., et al. Fluorescence properties and functional roles of tryptophan residues 60d, 96,148, 207, and 215 of thrombin. J Biol Chem 2759380 (2000) 29513-29520
43. Boffa M.B., Wang W., Bajzar L., and Nesheim M.E. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 273 4 (1998) 2127-2135
44. Kokame K., Zheng X., and Sadler J.E. Activation of thrombin-activatable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 273 (1998) 12135-12139
45. Tsai S.P., and Drayana D. The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13. Genomics 14 (1992) 549-550
46. Zhao L., Morser J., Bajzar L., Neisheim M., and Nagashima M. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 80 (1998) 949-955
47. Brouwers G.J., Vos H.L., Leebeek F.W., Bulk S., Scheineder M., and Boffa M. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 98 (2001) 1992-1993
48. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., and Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 277 (2002) 1021-1030
49. Boffa M.B., Bell R., Stevens W.K., and Nesheim M.E. Roles of thermal instability and proteolytic cleavage in regulation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 275 17 (2000) 12868-12878
50. Marx P.F., Hackeng T.M., Dawson P.E., Griffin J.H., Meijers J.C., and Bouma B.N. Inactivation of active thrombin-activatable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than a proteolytic cleavage. J Biol Chem 275 (2000) 12410-12415
51. Franco R.F., Fagundes M.G., Meijers J.C., et al. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86950 (2001) 510-517
52. Hori Y., Gabazza E.C., Yano Y., et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 87 2 (2002) 660-665
53. Van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin-activatable fibrinolysis inhibitor and risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
54. Eichinger S., Schonauer V., Weltermann A., et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103 (2004) 3773-3776
55. Zorio E., Castello R., Falco C., et al. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122 6 (2003) 958-965
56. Silveira A., Schatteman K., Grossens F., et al. Plasma carboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 84 (2000) 364-368
57. Van Thiel D.H., George M., and Fareed J. Low levels of thrombin-activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb Haemost 85 (2001) 667-670
58. Meijers J.C.M., Oudijk E.J.D., Mosnier L.O., et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 108 (2000) 518-523
59. Watanabe R., Wada H., Watanabe Y., et al. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 104 (2001) 1-6
60. Barrow J.C., Nantermet P.G., Stauffer S.R., et al. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as a novel antithrombotics. J Med Chem 46 25 (2003) 5294-5297
61. Polla M., Tottie L., Norden C., et al. Design and synthesis of the first potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem 12 5 (2004) 1151-1175
62. Suzuki K., Muto Y., Fushihara K., et al. Enhancement of fibrinolysis by EF6265, a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 309 2 (2004) 607-615
63. Chetaille P., Alessi M.C., Kouassi D., Morange P.E., and Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 83 6 (2000) 902-905
64. Chabloz P., Reber G., Boehlen F., Hohfeld P., and de Moerloose P. TAFI antigen and D-Dimer levels during normal pregnancy and at delivery. Br J Haematol 115 1 (2001) 150-152
65. Mousa H.A., Downey C., Alfirevic Z., and Toh C.H. Thrombin-activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost 92 5 (2004) 1025-1031
66. O'Riordan M.N., and Higgins J.R. Haemostasis in normal and abnormal pregnancy. Baillieres Best Pract Res Clin Obstet Gynaecol 17 (2003) 385-396
67. Antovic J.P., Rafik Hamad R., Antovic A., Blomback M., and Bremme K. Does thrombin-activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost 88 4 (2002) 644-647
68. Alacacioglu I., Ozcan M.A., Alacacioglu A., et al. Plasma levels of thrombin-activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb Res 114 3 (2004) 155-159
69. De Maat M.P., Jansen N.W., Hille E.T., et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2 9 (2004) 1588-1593
70. Rodie V.A., Freeman D.J., Sattar N., and Greer I.A. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy?. Atherosclerosis 175 (2004) 189-202
71. Coomarasamy A., Honest H., Papaionnou S., Gee H., and Khan K.S. Aspirin for prevention of preeclampsia: a systemic review. Obstet Gynecol 101 (2003) 1319-1332
72. Kupferminc M.J., Fait G., Many A., et al. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy 20 1 (2001) 35-44
73. Paternoster D.M., Fantinato S., Manganelli F., Nicolini U., Milani M., and Girolami A. Recent progress in the therapeutic management of pre-eclampsia. Expert Opin Pharmacother 5 11 (2004) 2233-2239
74. Knight M., Duley L., Henderson-Smart D.J., and King J.F. Antiplatelet agents for preventing and treating pre-eclampsia. Cochrane Database Syst Rev 2 (2000) CD000492
75. Levine R.J., Hauth J.C., Curet L.B., et al. Trial of calcium to prevent preeclampsia. N Engl J Med 337 2 (1997) 69-76
76. Belizan J.M., Villar J., and Repke J. The relationship between calcium intake and pregnancy-induced hypertension: Up-to-date evidence. Am J Obstet Gynecol 158 (1988) 898-902
77. Rytlewski K., Olszanecki R., Korbut R., and Zdebski Z. Effects of prolongated oral supplementation with L-arginine on blood pressure and nitric oxide synthesis in PEC. Eur J Clin Invest 35 (2005) 32-37
78. Makrides M., Duley L., and Oslen S.F. Fish oil, and other prostaglandin precursor supllementation during pregnancy for reducing pre-eclampsia, preterm birth, low birth weight and intrauterine growth restriction. Cochrane Database Syst Rev 4 (2001) CD003402
79. Raijmakers M.T.M., Dechend R., and Poston L. Oxidative stress and preeclampsia. Rationale for antioxidant clinical trials. Hypertension 44 (2004) 374-380
80. Chappell L.C., Seed P.T., Briley A.L., et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 354 (1999) 810-816
81. Sibai B.M. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 179 (1998) 1275-1278
82. Aagaard-Tillery K.M., and Belford M.A. Eclampsia: Morbidity, Mortality, and Management. Clin Obstet Gynecol 48 1 (2005) 12-23